OmniAb (OABI) Gross Margin (2024 - 2026)

OmniAb (OABI) reported Gross Margin of 99.9% for Q1 2026, down 3.0% year-over-year from 102.99% in Q1 2025, and little changed quarter-over-quarter from 99.89% in Q4 2025.

OmniAb (OABI) Gross Margin (2024 - 2026) Analysis & Trends

OmniAb (OABI) has 3 years of Gross Margin data on file, last reported at 99.9% in Q1 2026.

  • Gross Margin for Q1 2026 came in at 99.9%, down 3.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 98.91% (down 108.0% YoY), and the FY2025 annual result was 98.38%, down 162.0% from the prior year.
  • Gross Margin was little changed at 99.9% in Q1 2026 per OABI's latest filing, from 99.89% in the prior quarter.
  • Over five years, Gross Margin peaked at 100.0% in Q2 2024 and troughed at 93.28% in Q2 2025.
  • A 3-year average of 98.96% and a median of 99.91% in 2025 frame the typical range for Gross Margin.
  • The sharpest annual moves came in 2025 and 2026: Gross Margin plunged 672 bps in 2025, then declined 3 bps in 2026.
  • A 3-year view of Gross Margin shows it stood at 100.0% in 2024, then fell by 0 bps to 99.89% in 2025, then increased by 0 bps to 99.9% in 2026.
  • Business Quant data shows OABI's Gross Margin at 99.9% in Q1 2026, 99.89% in Q4 2025, and 98.7% in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 79.04%
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 86.85%
9 Abivax 91.96 Bn 91.96 Bn - -
10 OmniAb 294.96 Mn 252.00 Mn 14.41 Mn 99.90%

Historic Data

Download Data
DateValue
Mar 31, 2026 99.90%
Dec 31, 2025 99.89%
Sep 30, 2025 98.70%
Jun 30, 2025 93.28%
Mar 31, 2025 99.93%
Dec 31, 2024 100.00%
Sep 30, 2024 100.00%
Jun 30, 2024 100.00%